BR9205771A - Vetor de vírus recombinantes e processo para a fabricaçao do mesmo - Google Patents

Vetor de vírus recombinantes e processo para a fabricaçao do mesmo

Info

Publication number
BR9205771A
BR9205771A BR9205771A BR9205771A BR9205771A BR 9205771 A BR9205771 A BR 9205771A BR 9205771 A BR9205771 A BR 9205771A BR 9205771 A BR9205771 A BR 9205771A BR 9205771 A BR9205771 A BR 9205771A
Authority
BR
Brazil
Prior art keywords
virus vector
pct
nucleotide sequences
recombinant virus
pair
Prior art date
Application number
BR9205771A
Other languages
English (en)
Inventor
Michael Edward Griffith Boursnell
Stephen Charles Inglis
Alan James Munro
Original Assignee
Cantab Pharma Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantab Pharma Res filed Critical Cantab Pharma Res
Publication of BR9205771A publication Critical patent/BR9205771A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
    • C12P41/004—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of alcohol- or thiol groups in the enantiomers or the inverse reaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/62—Carboxylic acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR9205771A 1991-03-14 1992-03-10 Vetor de vírus recombinantes e processo para a fabricaçao do mesmo BR9205771A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919105383A GB9105383D0 (en) 1991-03-14 1991-03-14 An immunotherapeutic for cervical cancer
PCT/GB1992/000424 WO1992016636A1 (en) 1991-03-14 1992-03-10 Recombinant virus vectors encoding human papillomavirus proteins

Publications (1)

Publication Number Publication Date
BR9205771A true BR9205771A (pt) 1994-06-07

Family

ID=10691550

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9205771A BR9205771A (pt) 1991-03-14 1992-03-10 Vetor de vírus recombinantes e processo para a fabricaçao do mesmo

Country Status (17)

Country Link
US (1) US5719054A (pt)
EP (1) EP0576471B1 (pt)
JP (1) JPH06505626A (pt)
KR (1) KR100240183B1 (pt)
CN (1) CN1090239C (pt)
AT (1) ATE208824T1 (pt)
AU (1) AU665531B2 (pt)
BR (1) BR9205771A (pt)
CA (1) CA2106069A1 (pt)
DE (1) DE69232201T2 (pt)
DK (1) DK0576471T3 (pt)
ES (1) ES2168258T3 (pt)
GB (1) GB9105383D0 (pt)
MX (1) MX9205131A (pt)
NO (1) NO310033B1 (pt)
OA (1) OA10085A (pt)
WO (1) WO1992016636A1 (pt)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023570A1 (en) * 1992-05-11 1993-11-25 Pharmagenics, Inc. Oligonucleotides having conjugates attached at the 2'-position of the sugar moiety
US8062642B1 (en) 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
AT399656B (de) * 1993-03-19 1995-06-26 Boehringer Ingelheim Int Verfahren zur herstellung von krebsvakzinen
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US8956621B2 (en) * 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
AUPN015794A0 (en) 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
US5955087A (en) * 1995-02-24 1999-09-21 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
US6165460A (en) * 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)
AUPN443995A0 (en) * 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
FI990157A7 (fi) * 1996-07-29 1999-01-28 Cantab Pharmaceuticals Res Limited Immunoterapeuttisina aineina käyttökelpoisia polypeptidejä sekä polype ptidivalmistuksen menetelmiä
US7118754B1 (en) 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
DE19631357A1 (de) * 1996-08-02 1998-02-05 Deutsches Krebsforsch Vektor zur Aktivierung des Immunsystems gegen mit Papillomviren bzw. Sequenzen davon assoziierten Zellen
AU4556597A (en) * 1996-09-24 1998-04-17 Bavarian Nordic Research Institute A/S Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
ES2245052T3 (es) * 1997-12-01 2005-12-16 Fang Fang Anticuerpos de recombinacion multivalentes destinados para el tratamiento de infecciones debidas al rinovirus humano (hrv).
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
WO1999049029A1 (en) * 1998-03-20 1999-09-30 Benitec Australia Ltd Control of gene expression
US6541002B1 (en) 1998-03-30 2003-04-01 Thomas Jefferson University Compositions and methods for providing a protein to a virion
DE19819476C1 (de) * 1998-04-30 2000-01-05 Deutsches Krebsforsch Polypeptid mit immunogenen Eigenschaften und veränderten biologischen Funktionen eines Proteins
EP1728865A1 (en) * 1998-09-04 2006-12-06 Aventis Pasteur Limited Treatment of cervical cancer
US20030035798A1 (en) * 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
EP2100620A1 (en) * 1999-09-16 2009-09-16 Eisai Corporation of North America Nucleic acids encoding polyepitope polypeptides
AU2007201619B2 (en) * 1999-09-16 2011-05-12 Eisai Inc. Nucleic acids encoding polyepitope polypeptides
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
DK1274464T3 (da) 2000-03-13 2012-01-23 Engene Inc Sammensætninger og fremgangsmåder til regulering af proteinekspression i tarm
WO2001070763A1 (en) * 2000-03-22 2001-09-27 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
GB0105606D0 (en) * 2001-03-07 2001-04-25 Cantab Pharmaceuticals Res Ltd Immunogens and vaccines and their preparation and use
WO2002072789A2 (en) * 2001-03-12 2002-09-19 Irm, Llc. Genomics-driven high speed cellular assays, development thereof, and collections of cellular reporters
US20030170642A1 (en) * 2001-03-12 2003-09-11 Irm, Llc Identification of cellular targets for biologically active molecules
WO2002077012A2 (en) * 2001-03-23 2002-10-03 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Human papilloma virus immunoreative peptides
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
US20040091995A1 (en) * 2001-06-15 2004-05-13 Jeffrey Schlom Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
AUPR621501A0 (en) 2001-07-06 2001-08-02 Commonwealth Scientific And Industrial Research Organisation Delivery of ds rna
WO2003062370A2 (en) 2001-07-19 2003-07-31 Perlan Therapeutics, Inc. Multimeric proteins and methods of making and using same
AU2002364124A1 (en) * 2001-11-28 2003-06-10 The Burnham Institute Methods for identifying modulators of apoptosis
EP2269619A1 (en) * 2002-08-12 2011-01-05 Jennerex Biotherapeutics ULC Methods and compositions concerning poxviruses and cancer
MXPA05003395A (es) * 2002-10-03 2005-06-22 Wyeth Corp Polipeptidos de virus de papiloma humano y composiciones inmunogenas.
DE60332377D1 (de) * 2002-10-21 2010-06-10 Eisai Inc Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden
CA2516320C (en) 2003-02-18 2015-05-26 Kevin Slawin Induced activation in dendritic cells
DK1648931T3 (da) 2003-07-21 2011-03-07 Transgene Sa Multifunktionelle cytokiner
EP1732596A2 (en) * 2004-03-11 2006-12-20 Shantha West, Inc. Therapeutic use of rm1 antigen
EP1819732A2 (en) 2004-12-06 2007-08-22 Kirin Beer Kabushiki Kaisha Human monoclonal antibodies to influenza m2 protein and methods of making and using same
EP2567976B1 (en) 2005-03-23 2017-07-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
CN1308036C (zh) * 2005-03-28 2007-04-04 浙江大学医学院附属妇产科医院 一种hpv多肽疫苗及其制备方法
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
KR101772375B1 (ko) * 2005-09-07 2017-08-29 신라젠(주) Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법
CA2524619A1 (en) * 2005-11-22 2007-05-22 Ottawa Health Research Institute Novel stem cells, nucleotide sequences and proteins therefrom
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
WO2007127160A2 (en) * 2006-04-24 2007-11-08 Shantha West, Inc. Agrm2 antigen
CA2656266C (en) * 2006-06-20 2012-07-31 Transgene S.A. Recombinant viral vaccine
EP2426142A3 (en) * 2006-10-16 2012-06-13 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
CA2666667C (en) 2006-10-19 2023-06-20 Baylor College Of Medicine Generating an immune response by inducing cd40 and pattern recognition receptors
JP2010510772A (ja) 2006-11-27 2010-04-08 パトリス リミテッド 新生細胞における新規なグリコシル化ペプチド標的
WO2008092854A2 (en) * 2007-01-30 2008-08-07 Transgene S.A. Papillomavirus e2 polypeptide used for vaccination
KR20080084528A (ko) * 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
JP5474767B2 (ja) * 2007-05-15 2014-04-16 トランジェーヌ、ソシエテ、アノニム 多重遺伝子発現のためのベクター
WO2008150496A2 (en) * 2007-05-31 2008-12-11 Genelux Corporation Assay for sensitivity to chemotherapeutic agents
GB0710538D0 (en) * 2007-06-01 2007-07-11 Glaxo Group Ltd Vaccine
JP5213075B2 (ja) 2007-06-15 2013-06-19 ジェネラックス・コーポレイション 腫瘍の画像化および／または処置のための微生物
WO2009011924A1 (en) * 2007-07-18 2009-01-22 Genelux Corporation Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
EP2185694A2 (en) 2007-08-02 2010-05-19 California Stem Cell, Inc. Neuronal progenitor cells and methods of derivation and purification of neuronal progenitor cells from embryonic stem cells
EP2215231A4 (en) * 2007-10-15 2010-12-01 Univ Queensland EXPRESSION SYSTEM FOR MODULATING AN IMMUNE RESPONSE
CA2705869C (en) * 2007-11-19 2012-10-30 Philippe Erbs Poxviral oncolytic vectors
US8466259B2 (en) 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
US8426163B2 (en) 2007-12-07 2013-04-23 National Health Research Institutes Production of lipidated proteins in E. coli
EP2331680B1 (en) * 2008-09-22 2017-05-03 Baylor College Of Medicine Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters
US8211487B2 (en) * 2008-11-26 2012-07-03 Srinivasan Damodaran Inhibition of ice crystal growth
ES2571235T3 (es) 2009-04-10 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3
US8492119B2 (en) 2009-04-27 2013-07-23 Kyowa Hakko Kirin Co., Ltd Antibody to human IL-3 receptor alpha chain
US8287880B2 (en) 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
US8658176B2 (en) 2009-06-22 2014-02-25 National Health Research Institutes Lipidated tumor-associated antigens and immunotherapeutic compositions
BR112012005774B8 (pt) 2009-09-14 2023-02-14 Jennerex Inc uso de um inibidor de quinase antiangiogênico no tratamento de câncer
WO2011060233A1 (en) 2009-11-11 2011-05-19 The Trustees Of The University Of Pennsylvania Anti-tem1 antibodies and uses thereof
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
WO2011146862A1 (en) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Methods for inducing selective apoptosis
JP6153866B2 (ja) 2010-05-25 2017-06-28 キアゲン ガイサーズバーグ アイエヌシー． 迅速なハイブリッド捕捉アッセイ、及び関連する戦略的に切断されたプローブ
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
KR101942237B1 (ko) 2011-01-04 2019-01-25 신라젠(주) 종양 항원에 대한 항체의 생산 및 종양용해 우두 바이러스의 투여에 의한 종양 특이적 보체 의존적 세포독성의 생산
CN114262690A (zh) 2011-04-15 2022-04-01 吉恩勒克斯公司 减毒的痘苗病毒的克隆毒株及其使用方法
WO2013006486A2 (en) 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
BR112014015016B1 (pt) 2011-12-21 2023-10-03 Nykode Therapeutics ASA Proteína homodimérica de duas cadeias de aminoácidos idênticas,cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica,célula hospedeira, método de preparação de uma proteína homodimérica, método de preparação de uma vacina e vacina
WO2013138522A2 (en) 2012-03-16 2013-09-19 Genelux Corporation Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2013158265A1 (en) 2012-04-20 2013-10-24 Genelux Corporation Imaging methods for oncolytic virus therapy
WO2013162748A1 (en) 2012-04-27 2013-10-31 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (tem1) antibody variants and uses thereof
CN102787134B (zh) * 2012-07-20 2014-11-05 西安交通大学 一种用于同源重组的自转运载体及其构建的经粘膜免疫疫苗
US20140140959A1 (en) 2012-10-05 2014-05-22 Aladar A. Szalay Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
JP6430949B2 (ja) 2012-10-23 2018-11-28 エモリー ユニバーシティ Ｇｍ−ｃｓｆとｉｌ−４のコンジュゲート、組成物、ならびにそれに関連する方法
AU2013337926B2 (en) 2012-10-30 2017-12-21 Esperance Pharmaceuticals, Inc. Antibody/drug conjugates and methods of use
HK1214832A1 (zh) 2012-11-28 2016-08-05 恩格姆生物制药公司 用於代謝病症和疾病治療的組合物和方法
MX383664B (es) 2012-12-27 2025-03-14 Ngm Biopharmaceuticals Inc Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
EP2953970A4 (en) 2013-02-08 2016-06-29 Misfolding Diagnostics Inc TRANSTYRETIN ANTIBODIES AND USES THEREOF
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
WO2014151960A2 (en) 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
CA2912172A1 (en) 2013-06-05 2014-12-11 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides
US20160152952A1 (en) 2013-06-25 2016-06-02 Temple University-Of The Commonwealth System Of Higher Education Cortical Bone-Derived Stem Cells
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
CN103772508B (zh) * 2014-01-15 2017-05-10 深圳泰来生物医药有限公司 免疫增强的人乳头瘤病毒感染及相关疾病的治疗性疫苗
US10934346B2 (en) 2014-02-14 2021-03-02 Bellicum Pharmaceuticals, Inc. Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12
US10888608B2 (en) 2014-09-02 2021-01-12 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides
CN114129709A (zh) 2014-10-23 2022-03-04 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
ES2904301T3 (es) 2014-11-03 2022-04-04 Academisch Ziekenhuis Leiden H O D N Leids Univ Medisch Centrum Receptores de células T dirigidos contra Bob1 y usos de los mismos
US10350245B2 (en) 2015-01-21 2019-07-16 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
US9901639B2 (en) 2015-02-13 2018-02-27 Temple University—Of the Commonwealth System of Higher Education Bone marrow origin progenitor cell or endothelial progenitor cell in combination with DNMT1 gene therapy for vascular repair in metabolic disease
JP2018510627A (ja) 2015-03-10 2018-04-19 レイデン ユニバーシティ メディカル センター メラノーマ優先発現抗原に対して向けられたｔ細胞レセプターおよびその使用
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
WO2017096432A1 (en) 2015-12-09 2017-06-15 Admedus Vaccines Pty Ltd Immunomodulating composition for treatment
JP2019505512A (ja) 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
KR102466763B1 (ko) 2016-04-13 2022-11-11 오리맵스 리미티드 항- psma 항체 및 이의 용도
US10512683B2 (en) * 2017-03-03 2019-12-24 Papivax Biotech Inc. Combination therapies for human papillomavirus-associated diseases comprising administration of therapeutic vaccine and recombinant virus vector
WO2018208849A1 (en) 2017-05-09 2018-11-15 Bellicum Pharmaceuticals, Inc. Methods to augment or alter signal transduction
JP2020531514A (ja) 2017-08-22 2020-11-05 モナシュ・ユニヴァーシティ 終末糖化産物受容体（ｒａｇｅ）の活性化のスクリーニングアッセイ、モジュレーター及び調節
IL273245B2 (en) 2017-09-15 2025-03-01 Commw Scient Ind Res Org RNA molecules
EP3720479A2 (en) 2017-12-08 2020-10-14 Bellicum Pharmaceuticals, Inc. Methods for enhancing and maintaining car-t cell efficacy
EP3849565A4 (en) 2018-09-12 2022-12-28 Fred Hutchinson Cancer Research Center REDUCTION OF CD33 EXPRESSION TO SELECTIVELY PROTECT THERAPEUTIC CELLS
JP2024502832A (ja) 2020-12-31 2024-01-23 アラマー バイオサイエンシーズ， インコーポレイテッド 高親和性及び／または特異性を有する結合剤分子ならびにその製造及び使用方法
CA3260631A1 (en) 2022-07-08 2024-01-11 Viromissile, Inc. Oncolytic and recombinant vaccine viruses and their methods of use
CN119464385B (zh) * 2024-12-04 2026-04-07 华中科技大学同济医学院附属同济医院 Matv11重组腺病毒载体、应用、制备方法及hpv治疗性疫苗

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338683A (en) * 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
FR2643817B1 (fr) * 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
EP0469089B1 (en) * 1989-04-18 1997-11-19 Applied Biotechnology, Inc. Generation of hybrid genes and proteins by virus-mediated recombination

Also Published As

Publication number Publication date
EP0576471B1 (en) 2001-11-14
NO933260D0 (no) 1993-09-13
OA10085A (en) 1996-12-18
JPH06505626A (ja) 1994-06-30
DE69232201T2 (de) 2002-07-11
AU665531B2 (en) 1996-01-11
EP0576471A1 (en) 1994-01-05
DK0576471T3 (da) 2002-03-11
CN1064892A (zh) 1992-09-30
HK1001657A1 (en) 1998-07-03
WO1992016636A1 (en) 1992-10-01
AU1414792A (en) 1992-10-21
ATE208824T1 (de) 2001-11-15
MX9205131A (es) 1994-06-30
DE69232201D1 (de) 2001-12-20
CA2106069A1 (en) 1992-09-15
NO933260L (no) 1993-10-22
US5719054A (en) 1998-02-17
GB9105383D0 (en) 1991-05-01
ES2168258T3 (es) 2002-06-16
CN1090239C (zh) 2002-09-04
NO310033B1 (no) 2001-05-07
KR100240183B1 (ko) 2000-01-15

Similar Documents

Publication Publication Date Title
BR9205771A (pt) Vetor de vírus recombinantes e processo para a fabricaçao do mesmo
KR900700508A (ko) 인간의 호흡기 합포체성 바이러스에 대한 당단백질 면역 단편을 함유하는 키메라(chimeric) 당단백질
HUP9802217A2 (hu) Rekombináns MVA-vírus és alkalmazása
WO2021000968A3 (zh) 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗
ES8505719A1 (es) Procedimiento de preparar mutantes de delecion vivos y metodo de preparar vacunas
DE69828193D1 (de) Hyaluronan synthase gen und seine verwendung
DE69430071D1 (de) Herstellung von rekombinanten proteinen in einem rinderadenovirus-expressionsvektorsystem
FI964592A0 (fi) Papilloomavirusrokotteita
EP0575491A4 (de) Gentechnologisch hergestellter stamm für impfstoffe.
MXPA02006888A (es) Flavivirus recombinantes y metodos para utilizar los mismos.
DE3853139D1 (de) Rekombinanter, fremde gene enthaltender menschlicher cytomegalovirus und seine verwendung.
MY110899A (en) Dengue virus
DE69333751D1 (de) Nicht-verbreitendes lebendes herpesvirusvakzin
NO922728L (no) Vaksine mot coccidiose
DE69929530D1 (de) Attenuierte pferdeherpesvirus
NO20032097L (no) Gj¶ravledet vaksine mot IPNV
ATE223492T1 (de) Mutanten des infektiösen rinder rhinotracheitis- virus und impfstoffe
RU2000122617A (ru) Самореплицирующийся рекомбинантный вектор, способ его получения, вакцина для иммунизации против вич с помощью днк, содержащая указанный вектор, способ лечения или профилактики вич и клетка-хозяин, содержащая указанный вектор
IL168374A (en) Vaccines against west nile virus
RU93056615A (ru) Вектор, способ получения вектора, способ получения лекарственного препарата, способ активизации иммунитета
WO1992014818A3 (en) Entomopoxvirus expression system comprising spheroidin or thymidine-kinase sequences
ES2074965A1 (es) Virus mutante recombinante de rinotraqueitis infecciosa bovina y vacunas que lo contienen.
WO2024259078A3 (en) Anti-tick vaccines and methods of use thereof
WO2002078621A3 (en) Replication-competent recombinant virus and methods of use thereof
BR9506666A (pt) Construçao de DNA vetor de express o replicável processo para a preparaçao de uma bactéria atenuada célula hospedeira composiçao de vacina e processo para o tratamento ou profilaxia de uma infecçao em um mamifero por exemplo um humano

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal
CKFC Appeal: appeal against refusal